Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Birgit Girshick

At a glance: Birgit Girshick is CEO at Charles River Laboratories (CRL). Their latest SEC Form 4, filed Aug 13, 2026, reported a sale of $1.8M. On file: 0 purchase lines ($0) and 1 sale line ($1.8M).

Disclosed holdings: about $11.8M of CRL stock: 36,013 shares reported on their latest Form 4 (filed Aug 13, 2026), valued at the Nov 19, 2026 close of $328.62. This counts only CRL shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

CEO at Charles River Laboratories International, Inc. (CRL)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $1.8M

Birgit Girshick's InsiderPrint

3 trades from SEC Form 4 filings, 2023 to 2026, drawn as one fingerprint.

InsiderPrint of Birgit Girshick: 3 trades, 2023 to 20262023: 1 buy, 0 sales2024: 0 buys, 0 sales2025: 1 buy, 0 sales2026: 0 buys, 1 sale

Reading this print: Mostly buys, trading about once a year, typically $249K a trade; most sales are on a pre-planned 10b5-1 schedule.

  • Bump outward: a purchase (2)
  • Dent inward: a sale (1)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Mark ZoradiDirector · CNK · 100% matchTheir buys since 2020: 1 of 3 beat the S&P 500
  2. K. Michelle BorninkhofPresident · AZO · 99% match
  3. Paul M. BarbasDirector · VST · 99% match
  4. Stuart BoddenCEO · RNGR · 98% match
  5. Richard A. WiddicombeChair · HRTG · 98% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2023

From the SEC's insider data sets: each open-market buy by Birgit Girshick, matched to how the stock did over the next 90 days against the S&P 500.

1 of 2 buys beat the S&P 500 (50%), median +1.2% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
CRLFeb 21, 2025-14.3%
CRLNov 21, 2023+16.8%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Aug 13SEC CRLCharles River Laboratories International, Inc. Sell Plan 6,50036,013 held (−15%) $279.90 $1.8M +17.4%
  • Sell

    CEO Birgit Girshick sold $1.8M of CRL at $279.90 — pre-scheduled 10b5-1 plan sale.

Follow Birgit Girshick

Get one email when Birgit Girshick files a new purchase or sale. Free.

At most one email a day about Birgit Girshick, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.